Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC, Quartino A, Polhamus D, Riggs M, French J, Wang X, Vadhavkar S, Smitt M, Hoersch S, Strasak A, Jin JY, Girish S, Li C. Chen SC, et al. Among authors: hoersch s. Br J Clin Pharmacol. 2017 Dec;83(12):2767-2777. doi: 10.1111/bcp.13381. Epub 2017 Sep 3. Br J Clin Pharmacol. 2017. PMID: 28733983 Free PMC article. Clinical Trial.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Krop IE, et al. Among authors: hoersch s. Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526538 Clinical Trial.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Diéras V, et al. Among authors: hoersch s. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL. Shah MA, et al. Among authors: hoersch s. Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31. Gastric Cancer. 2019. PMID: 30706247 Clinical Trial.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA. Perez EA, et al. Among authors: hoersch s. Cancer. 2019 Nov 15;125(22):3974-3984. doi: 10.1002/cncr.32392. Epub 2019 Jul 18. Cancer. 2019. PMID: 31318460 Free article.
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J Jr, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S. O'Shaughnessy J, et al. Among authors: hoersch s. Clin Cancer Res. 2015 Oct 1;21(19):4305-11. doi: 10.1158/1078-0432.CCR-15-0636. Epub 2015 Jun 3. Clin Cancer Res. 2015. PMID: 26041745 Clinical Trial.
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S; NO16853 trial group. Buzdar AU, et al. Among authors: hoersch s. Ann Oncol. 2012 Mar;23(3):589-597. doi: 10.1093/annonc/mdr256. Epub 2011 Jun 1. Ann Oncol. 2012. PMID: 21633047 Free article. Clinical Trial.
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG. Schmoll HJ, et al. Among authors: hoersch s. J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324362 Clinical Trial.
Benchmarking tools for transcription factor prioritization.
Santana LS, Reyes A, Hoersch S, Ferrero E, Kolter C, Gaulis S, Steinhauser S. Santana LS, et al. Among authors: hoersch s. Comput Struct Biotechnol J. 2024 May 11;23:2190-2199. doi: 10.1016/j.csbj.2024.05.016. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38817966 Free PMC article.
Integrative Proteogenomics for Differential Expression and Splicing Variation in a DM1 Mouse Model.
Solovyeva EM, Utzinger S, Vissières A, Mitchelmore J, Ahrné E, Hermes E, Poetsch T, Ronco M, Bidinosti M, Merkl C, Serluca FC, Fessenden J, Naumann U, Voshol H, Meyer AS, Hoersch S. Solovyeva EM, et al. Among authors: hoersch s. Mol Cell Proteomics. 2024 Jan;23(1):100683. doi: 10.1016/j.mcpro.2023.100683. Epub 2023 Nov 21. Mol Cell Proteomics. 2024. PMID: 37993104 Free PMC article.
40 results